Tim Keith of Genome Therapeutics and his colleagues conducted genome-wide scans of 460 Caucasian families, each of which had at least two children with doctor-diagnosed asthma. They found that a gene called ADAM33 is strongly associated with both increased occurrence of asthma and inflammation of the airways, one of the main components of asthma. As it turns out, this makes sense because the protein that this gene encodes is expressed in human lung and muscle cells. "The airways in asthma patients undergo a number of changes, such as thickening of the airway walls and subsequent narrowing of the airway passage," team member Stephen Holgate explains. "These changes contribute to the overall airway responsiveness and related breathing problems in asthma. Our studies suggest ADAM33 plays a role in this remodeling and may underlie abnormalities in asthmatic airway function."
Knowing that a person possesses a disease-linked variant of this particular gene could one day enable doctors to begin early preventative treatment. "This research has provided not only a novel target for drug discovery, but also insights into the pathways and pathogenic mechanisms underlying asthma," remarks Cecil B. Pickett, president of the Schering-Plough Research Institute in Kenilworth, N. J., home to many of the studys researchers. Right now, doctors must treat asthma after it has already begun to suck the breath out of its victims. Perhaps in the future, we can stop the disease before it even starts.